US Patent

US11793798 — Pharmaceutical formulations comprising a pyridylaminoacetic acid compound

Method of Use · Assigned to Santen Pharmaceutical Co Ltd · Expires 2035-01-08 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical preparation for treating or preventing glaucoma or ocular hypertension that contains a specific pyridylaminoacetic acid compound.

USPTO Abstract

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

Drugs covered by this patent

omidenepag-isopropyl (OMIDENEPAG ISOPROPYL)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3454`	—	omidenepag-isopropyl

Patent Metadata

Patent number: US11793798
Jurisdiction: US
Classification: Method of Use
Expires: 2035-01-08
Drug substance claim: No
Drug product claim: Yes
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.